Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Cash from Operations (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Cash from Operations readings, the most recent being 3073000.0 for Q1 2026.

  • On a quarterly basis, Cash from Operations rose 89.08% to 3073000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 25875000.0, a 61.52% increase, with the full-year FY2025 number at 50940000.0, up 25.87% from a year prior.
  • Cash from Operations hit 3073000.0 in Q1 2026 for Atara Biotherapeutics, up from 5697000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 3073000.0 in Q1 2026 to a low of 84529000.0 in Q1 2022.
  • Median Cash from Operations over the past 5 years was 29612000.0 (2024), compared with a mean of 34478647.06.
  • Biggest five-year swings in Cash from Operations: surged 92.23% in 2024 and later crashed 145.35% in 2025.
  • Atara Biotherapeutics' Cash from Operations stood at 56880000.0 in 2022, then rose by 11.38% to 50406000.0 in 2023, then skyrocketed by 51.45% to 24471000.0 in 2024, then surged by 76.72% to 5697000.0 in 2025, then soared by 46.06% to 3073000.0 in 2026.
  • The last three reported values for Cash from Operations were 3073000.0 (Q1 2026), 5697000.0 (Q4 2025), and 9787000.0 (Q3 2025) per Business Quant data.